<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039572</url>
  </required_header>
  <id_info>
    <org_study_id>BIDMC-E-010284FB</org_study_id>
    <secondary_id>CDR0000069398</secondary_id>
    <secondary_id>NEDH-E-010284FB</secondary_id>
    <secondary_id>NCI-V02-1702</secondary_id>
    <nct_id>NCT00039572</nct_id>
  </id_info>
  <brief_title>Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain</brief_title>
  <official_title>A Phase I/II Trial For Neutron Capture Therapy In Glioblastoma Multiforme And Intracranial Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells&#xD;
      without harming normal tissue.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in&#xD;
      treating patients who have glioblastoma multiforme or melanoma metastatic to the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the time course, uniformity, and severity of acute and chronic normal tissue&#xD;
           reactions in patients with glioblastoma multiforme or intracranial melanoma treated with&#xD;
           boronophenylalanine-fructose complex (BPA-f) followed by cranial neutron irradiation&#xD;
           using a new fission converter beam facility.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of cranial neutron capture therapy in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine, through serial objective measurements, the clinical response in patients&#xD;
           treated with this therapy.&#xD;
&#xD;
        -  Determine the pharmacokinetics of BPA-f in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of cranial neutron capture therapy (NCT).&#xD;
&#xD;
      Patients receive boronophenylalanine-fructose complex IV over 90 minutes followed by cranial&#xD;
      NCT on days 1 and 2.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of NCT until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, additional patients&#xD;
      are treated at the MTD.&#xD;
&#xD;
      Patients are followed at 1, 2, 4, 6, 9, and 12 months and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>boronophenylalanine-fructose complex</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme OR&#xD;
&#xD;
          -  Radiographically diagnosed brain metastases after a diagnosis of melanoma&#xD;
&#xD;
          -  Contrast-enhanced tumor volume must not exceed 60 mL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prior severe cardiac disease, including the following:&#xD;
&#xD;
               -  Uncontrolled arrhythmias or conduction defects&#xD;
&#xD;
               -  Unstable or newly diagnosed angina pectoris&#xD;
&#xD;
               -  Recent coronary artery disease&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after study&#xD;
&#xD;
          -  No prior phenylketonuria&#xD;
&#xD;
          -  No cognitive impairment that would preclude informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior cranial irradiation&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M. Busse, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Institute of Technology</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2002</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

